Medivation

Short-sellers continued to be selective in the leading biotech stocks in the most recent period. Biogen and Medivation saw sharp drops in their short interest in early October. The number of Amgen shares short surged during that time. In the wake of ongoing market volatility and...

While short interest in most of the leading biotechs and emerging pharmaceuticals shrank between the March 31 and April 15 settlement dates, three stocks bucked that trend. Juno Therapeutics Inc (NASDAQ: JUNO) and Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) saw the number of their shares...

While Amgen (NASDAQ: AMGN) saw a sizable dip in short interest between the April 30 and May 15 settlement dates, short sellers piled on Medivation (NASDAQ: MDVN) and Pharmacyclics (NASDAQ: PCYC). Among other leading biotechs and emerging pharmaceuticals, gains in the number of their shares sold...

Biotech stocks have proved to be volatile this year, and short sellers piled on Incyte (NASDAQ: INCY) between the April 15 and April 30 settlement dates. Pharmacyclics (NASDAQ: PCYC) and Regeneron Pharmaceuticals (NASDAQ: REGN) also saw double-digit percentage increases in the number of their...

In a period when many biotech stocks were slipping, short sellers moved on many of the leading biotech and emerging pharmaceuticals between the March 14 and March 31 settlement dates. But Amgen (NASDAQ: AMGN), Celgene (NASDAQ: CELG) and Dendreon (NASDAQ: DNDN) were among those that bucked the...

After largely shying away in the previous period, short sellers found renewed interest in many of the leading biotech and emerging pharmaceutical companies between the February 28 and March 14 settlement dates. But Celgene (NASDAQ: CELG), Medivation (NASDAQ: MDVN) and Pharmacyclics (NASDAQ: PCYC...

Short interest in most of the leading biotech and emerging pharmaceutical companies declined between the February 14 and February 28 settlement dates. But Biogen Idec (NASDAQ: BIIB), BioMarin Pharmaceutical (NASDAQ: BMRN) and Medivation (NASDAQ: MDVN) bucked that trend. Short interest in Gilead...

U.S. stocks were mixed despite the S&P 500 hitting new all time highs of 1,867.92. Rumors surrounding Russian military involvement in Ukraine naturally presented investor concerns and fear in the market. The market was boosted by a positive consumer sentiment and a steady existing-home...

Among the leading biotech and emerging pharmaceutical companies, Amgen (NASDAQ: AMGN), Biogen Idec (NASDAQ: BIIB) and BioMarin Pharmaceutical (NASDAQ: BMRN) saw the largest percentage increases in short interest between the January 31 and February 15 settlement dates. Alexion Pharmaceuticals,...

Among the leading biotech and emerging pharmaceutical companies, Incyte (NASDAQ: INCY) and Pharmacyclics (NASDAQ: PCYC) saw the largest percentage declines in short interest between the January 15 and January 31 settlement dates. Short sellers shied away from Alexion Pharmaceuticals, Amgen, Biogen...

Among the leading biotech and emerging pharmaceutical companies, Biogen Idec (NASDAQ: BIIB), BioMarin Pharmaceutical (NASDAQ: BMRN) and Medivation (NASDAQ: MDVN) saw the most significant upswings between the December 31 and January 15 settlement dates. Gilead Sciences, Pharmacyclics and Regeneron...

The number of shares sold short in leading biotech and emerging pharmaceutical companies mostly declined between the December 13 and December 31 settlement dates. BioMarin Pharmaceutical (NASDAQ: BMRN), Celgene (NASDAQ: CELG) and Dendreon (NASDAQ: DNDN) led that trend. Short sellers also shied...

Among leading biotech and emerging pharmaceutical companies, the number of shares sold short in Amgen (NASDAQ: AMGN), Gilead Sciences (NASDAQ: GILD) and Pharmacyclics (NASDAQ: PCYC) grew by the largest percentages between the November 29 and December 13 settlement dates. Medivation saw its short...

Here is a quick look three top-performing biotech stocks with a consensus recommendation of analysts of Strong Buy. They are Medivation (NASDAQ: MDVN), Synageva BioPharma (NASDAQ: GEVA) and Optimer Pharmaceuticals (NASDAQ: OPTR). Medivation This San Francisco-based biopharmaceutical company...